Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Guo&Amp;'s Distal Entry Tear Repair With WeFlow-EndoPatch System (Gallant Study)

NCT: NCT06945809 · RECRUITING

NCT IDNCT06945809
StatusRECRUITING
Start Date2026-07-13
Completion2032-10
SponsorHangzhou Endonom Medtech Co., Ltd. (INDUSTRY)
First posted
Last updated

Brief Summary

A Multicenter, Randomized Controlled Study About the Safety and Efficacy of WeFlow-EndoPatch Aortic Endovascular Patch System manufactured by EndoNom Medtech (Hangzhou) Co., Ltd. for Chronic Aortic Dissection . (GALLANT Study)

Frequently Asked Questions

What is Guo&Amp;'s Distal Entry Tear Repair With WeFlow-EndoPatch System (Gallant Study)?

Guo&Amp;'s Distal Entry Tear Repair With WeFlow-EndoPatch System (Gallant Study) is a clinical trial registered under NCT06945809. Current status: RECRUITING.

What is the status of NCT06945809?

The current status of NCT06945809 (Guo&Amp;'s Distal Entry Tear Repair With WeFlow-EndoPatch System (Gallant Study)) is: RECRUITING.

When did Guo&Amp;'s Distal Entry Tear Repair With WeFlow-EndoPatch System (Gallant Study) start?

Guo&Amp;'s Distal Entry Tear Repair With WeFlow-EndoPatch System (Gallant Study) started on 2026-07-13.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑